- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02242799
Dolutegravir Interactions With Artemisinin-based Combination Therapies (DolACT)
Evaluation of Dolutegravir Interactions With Artemether-Lumefantrine and Amodiaquine-Artesunate
Study Overview
Status
Intervention / Treatment
Detailed Description
More than 90% of the malaria occurs in sub-Saharan Africa (WHO 2008), the region bearing 67% of the global HIV burden (WHO 2011). Given the extensive overlap in geographical distribution of these diseases, interactions between them could have profound public health consequences. Significant biological interactions exist between HIV and malaria. HIV is known to increase susceptibility to malaria infection (Whitworth, Morgan et al. 2000), compromise the host's ability to clear malaria parasites (characterised by higher parasite densities) (Francesconi, Fabiani et al. 2001), increase the risk of symptomatic malaria and contribute to malaria treatment failure (Hewitt, Steketee et al. 2006). In areas of unstable transmission, malaria mortality is higher in HIV-positive individuals. Additionally, placental malaria infection in HIV positive individuals is associated with higher perinatal mortality, low birth weight and HIV transmission, and this effect is not attenuated in subsequent pregnancies, in contrast with HIV-negative individuals. Conversely, malaria infection has been shown to increase HIV viral load (Hoffman, Jere et al. 1999, Kublin, Patnaik et al. 2005), with the potential for both accelerated HIV disease progression and increased HIV transmission (Abu-Raddad, Patnaik et al. 2006).
As of September 2011, Uganda had 1.4 million people living with HIV/AIDS; of those with clinically advanced disease, 54% (313 117) were receiving ART (WHO). As southern African countries are scaling up coverage of ART, they have also stepped up the fight against Pf malaria by increasing the coverage of Insecticide Treated Nets and by adopting the use of artemisinin-based combination therapies (ACTs) as first line treatment of malaria (USAID 2011). AL and AS-AQ are the most commonly utilized regimens in sub-Saharan Africa for first line treatment for malaria (WHO 2008).
As a consequence of high rates of HIV-malaria co-infection and increasing availability of both ACTs and ART in southern Africa, progressively more co-infected people will receive both classes of drugs. However, the pharmacokinetics, safety and/or efficacy of ACTs such as AL, AS-AQ and DHA-piperaquine in HIV-infected individuals who are on ART are poorly understood. Many efficacy studies conducted as part of the drug development process of ACTs have either not assessed the HIV status of study participants or systematically excluded HIV-infected individuals. Few studies have systematically evaluated for potential drug-drug interactions in a healthy volunteer setting.
Study Design
Open label, fixed sequence healthy volunteer study to compare pharmacokinetic interactions between DTG and AL (Study A; crossover design), or AS-AQ (Study B; parallel group design). Whilst a cross-over study design would be theoretically ideal for investigating both ACTs in combination with DTG, desethylamodiaquine, an active metabolite of AQ has an extensive terminal t1/2 of approximately 10 days; therefore it is not considered feasible to undertake a cross-over design for this arm of the study, since the washout period between the two phases would exceed two months, risking subject attrition. Furthermore, during that time period, intercurrent illnesses and other important changes may occur within a subject, leading changes in eligibility for the study. Therefore, two study designs are planned as detailed in the Study Design Section.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Kampala, Uganda
- Infectious Diseases Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Evidence of a personally signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study.
- Participants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- Men and women aged 18 years and above
- Weight ≥40 kg
- HIV antibody negative at screening.
- Malaria blood film negative at screening
- Willing to use mosquito bednets routinely for the duration of the study
- Women of childbearing potential must be willing to use an effective barrier contraception method for the duration of the study.
Exclusion Criteria:
- Significant disease affecting cardiac, respiratory, gastrointestinal or neurological symptoms which in the clinician's medical judgment could be worsened by participating in this study or the presence of medical or surgical conditions which could prevent the subject from complying with study procedures.
- Serum alanine transaminase (ALT) levels above 3x upper limit of normal
- Serum creatinine levels above 2x upper limit of normal
- Hepatitis B surface antigen positive
- Use of medications which are known inducers/inhibitors of CYP or glucuronyl transferase UGT1A1 within past 2 months (e.g. anticonvulsants, TB medications, HIV agents for prophylaxis, azole antifungals)
- Evidence of QT prolongation on electrocardiogram (ECG) QTc (Rate adjusted QT interval) >450ms (men) or >470ms (women)
- Pregnant women or female subjects who are unwilling to use a suitable contraceptive method for the duration of the study (condom, diaphragm, IUD or contraceptive implant)
- Likely to be poorly adherent based on clinician's medical judgement
- Known to be current injection drug user
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study A Sequence 1
Artemether-lumefantrine combination alone for 3 days with PK sampling at steady state, then 21 day washout period followed by Dolutegravir 50mg od dosing to steady state (7 days) with PK sampling then a further 3 days where Artemether-lumefantrine combination and Dolutegravir 50mg od are given together, with PK sampling at steady state.
|
Dolutegravir 50mg once daily will be given either alone or in combination, as specified
Other Names:
Artemether-lumefantrine combination will be given both alone and in combination with Dolutegravir 50mg od in order to assess changes in PK
Other Names:
|
Experimental: Study A Sequence 2
Dolutegravir 50mg od given for 7 days with PK sampling at steady state, followed immediately by a further 3 days where Artemether-lumefantrine combination and Dolutegravir 50mg od are given together, again with PK sampling at steady state.
Following a 21 day washout period, the subject will then receive Artemether-lumefantrine combination alone for 3 days, with PK sampling at steady state.
|
Dolutegravir 50mg once daily will be given either alone or in combination, as specified
Other Names:
Artemether-lumefantrine combination will be given both alone and in combination with Dolutegravir 50mg od in order to assess changes in PK
Other Names:
|
Experimental: Study B Sequence 1
Administration of artesunate-amodiaquine for 3 days with PK sampling at steady state
|
Artesunate-amodiaquine will be given alone or in combination with Dolutegravir 50mg od (in a parallel study design) in order to assess the potential interaction causing changes in PK parameters
Other Names:
|
Experimental: Study B Sequence 2
Dolutegravir alone for 7 days with PK sampling at steady state, followed immediately by administration of both artesunate-amodiaquine and dolutegravir together for a further 3 days with PK sampling at steady state
|
Dolutegravir 50mg once daily will be given either alone or in combination, as specified
Other Names:
Artesunate-amodiaquine will be given alone or in combination with Dolutegravir 50mg od (in a parallel study design) in order to assess the potential interaction causing changes in PK parameters
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in area under time-concentration curve [AUC] of DTG and antimalarial drugs
Time Frame: At steady state (after 3 days dosing for antimalarials and 7 days for DTG)
|
When subjects are at steady state (of single drug or combination, as detailed in the study design section) intensive PK sampling will be performed
|
At steady state (after 3 days dosing for antimalarials and 7 days for DTG)
|
Change in maximum concentration [Cmax] of DTG and antimalarials
Time Frame: At steady state (3 days for antimalarials and 7 days for DTG)
|
PK sampling will be done when each drug is at presumed 'steady state'
|
At steady state (3 days for antimalarials and 7 days for DTG)
|
Change in time to maximum concentration [Tmax] for antimalarials and DTG
Time Frame: At steady state (3 days for antimalarials and 7 days for DTG)
|
Medications will be dosed up to steady state before PK sampling is undertaken
|
At steady state (3 days for antimalarials and 7 days for DTG)
|
Change in clearance [Cl/F] for antimalarials and DTG
Time Frame: Steady state - 3 days for antimalarials and 7 days for dolutegravir
|
Medications will be dosed up to steady state prior to PK sampling
|
Steady state - 3 days for antimalarials and 7 days for dolutegravir
|
Change in trough concentration [Ctrough]) for antimalarial drugs and DTG
Time Frame: Steady state - 3 days for antimalarials and 7 days for DTG
|
PK sampling will be performed at steady state
|
Steady state - 3 days for antimalarials and 7 days for DTG
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of the drug combinations
Time Frame: Until 2 weeks after all medication has been discontinued at the end of study
|
Patients will be assessed clinically to identify safety concerns, panels of 'safety bloods' will be performed at the time of rich PK sampling, and 12 lead ECGs will assess potential effects of the drugs/ combinations on the QT interval
|
Until 2 weeks after all medication has been discontinued at the end of study
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Mohammed Lamorde, PhD, MBChB, Infectious Diseases Institute
- Principal Investigator: Saye H Khoo, FRCP, PhD, University of Liverpool
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Malaria
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antineoplastic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- HIV Integrase Inhibitors
- Integrase Inhibitors
- Antimalarials
- Anthelmintics
- Schistosomicides
- Antiplatyhelmintic Agents
- Lumefantrine
- Artemether
- Artesunate
- Dolutegravir
- Artemether, Lumefantrine Drug Combination
- Amodiaquine
Other Study ID Numbers
- PK13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States
Clinical Trials on Dolutegravir 50mg od
-
University of LiverpoolViiV Healthcare; Makerere UniversityCompletedPregnancy | HIVUganda, South Africa
-
University of CalgaryNot yet recruitingChronic Migraine
-
Nordsjaellands HospitalUnknownInflammatory Bowel DiseaseDenmark
-
University Hospital OlomoucCompletedVentilator-Associated Pneumonia
-
ViiV HealthcareJanssen, LPCompleted
-
Jagiellonian UniversityCompleted
-
TBF Genie TissulaireTerminated
-
University Hospital Virgen de las NievesUnknown
-
TakedaCompletedJapanese Healthy Adult MaleJapan